Spravato (Esketamine) Treatment for Depression in Massachusetts and Maryland
Latest medical review on: May 5th, 2026. Medically reviewed by Instructor in Psychiatry at Harvard Medical School and Lumin Health Co-founder, Chief Medical Officer Dr. Ben Yudkoff.
What is Spravato (esketamine)?
Spravato (esketamine) is an FDA-approved nasal spray for treatment-resistant depression in adults. Approved by the FDA in March 2019, it works by modulating glutamate signaling through NMDA receptor antagonism—a mechanism distinct from SSRIs and the first new approach to depression treatment in over 30 years. Treatment is administered under medical supervision at REMS-certified Lumin Health locations.
Latest medical review on: May 5th, 2026. Medically reviewed by Instructor in Psychiatry at Harvard Medical School and Lumin Health Co-founder, Chief Medical Officer Dr. Ben Yudkoff.
How effective is esketamine (Spravato) for treatment-resistant depression?
Spravato delivers measurable improvement in treatment-resistant depression where conventional antidepressants have failed. In pivotal Phase 3 clinical trials, esketamine combined with a newly initiated oral antidepressant produced significantly greater reduction in depression symptoms than placebo plus antidepressant—often within the first week of treatment, not the typical 4–6 weeks SSRIs require.
What does the clinical research show about Spravato?
Esketamine, also known as Spravato, has garnered substantial attention in the scientific community for its efficacy in treating treatment-resistant depression. Rigorous clinical trials and studies such as this study here have reinforced its positive impact on individuals who have not responded adequately to conventional antidepressants.
Esketamine, also known as Spravato, has garnered substantial attention in the scientific community for its efficacy in treating treatment-resistant depression. Rigorous clinical trials and studies such as this study here have reinforced its positive impact on individuals who have not responded adequately to conventional antidepressants.
How quickly does Spravato work compared to traditional antidepressants?
Spravato's unique mechanism of action—targeting the brain's glutamate receptors—drives rapid onset of relief. Patients often report meaningful improvement within days rather than the 4–6 weeks typically required for SSRIs and SNRIs to take effect, marking a substantial departure from the slower pace of traditional treatments.
Spravato's unique mechanism of action—targeting the brain's glutamate receptors—drives rapid onset of relief. Patients often report meaningful improvement within days rather than the 4–6 weeks typically required for SSRIs and SNRIs to take effect, marking a substantial departure from the slower pace of traditional treatments.
How does Spravato (esketamine) work in the brain?
Spravato works through NMDA receptor antagonism, which modulates glutamate – the brain's primary excitatory neurotransmitter – and triggers rapid synaptic plasticity. This mechanism is fundamentally different from SSRIs, which target serotonin. By restoring glutamate balance, Spravato can rewire the neural circuits underlying depression within hours to days, not weeks.
What is glutamate modulation and how does it relieve depression?
Esketamine's interaction with glutamate receptors triggers neuroplasticity – the rewiring of neural connections in the brain. This rewiring can shift entrenched depressive thought patterns and restore healthy mood regulation. Unlike serotonin-targeting medications, glutamate modulation acts directly on the synaptic machinery thought to underlie chronic depression.
Esketamine's interaction with glutamate receptors triggers neuroplasticity – the rewiring of neural connections in the brain. This rewiring can shift entrenched depressive thought patterns and restore healthy mood regulation. Unlike serotonin-targeting medications, glutamate modulation acts directly on the synaptic machinery thought to underlie chronic depression.
How does Spravato compare to SSRIs and ketamine therapy?
Spravato (nasal esketamine) is one of several treatment options for depression, alongside oral SSRIs, intravenous (IV) ketamine, and intramuscular (IM) ketamine. Each works through a different mechanism, has a different onset time, and is covered by insurance differently. The table below compares the four most common modalities for depression and treatment-resistant depression.
Does insurance cover Spravato (esketamine) treatment?
Yes Spravato is covered by most major insurance plans for treatment-resistant depression, including Blue Cross Blue Shield, Anthem, Aetna, UnitedHealthcare, Cigna, and Medicare. As an FDA-approved medication delivered in a clinical setting, it qualifies for medical-benefit coverage rather than pharmacy-benefit. At Lumin Health, we work directly with insurers so most patients pay average co-pays of traditional office visits.
It's vital to understand that Spravato (esketamine) is covered by insurance for the treatment of treatment-resistant depression. This coverage underscores the recognition of Spravato's (esketamine) effectiveness in addressing a challenging form of depression.
What are typical out-of-pocket costs for Spravato?
For insured patients, out-of-pocket costs for Spravato treatment are typically minimal – often $10 to $25 per session for most major plans. Lumin Health works directly with your insurer to verify coverage upfront, handle prior authorizations, and minimize unexpected bills. Patients without coverage can ask about self-pay options during the consultation.
What does a Spravato treatment session feel like?
A typical Spravato session lasts about 2 hours. You self-administer the nasal spray under the direct observation of a Lumin Health clinician, then remain on-site for a 2-hour monitoring period as required by the FDA REMS protocol. Sessions take place in a private, comfortable room with a calm environment.
How long is a typical course of Spravato treatment?
The standard treatment course is twice weekly for the first 4 weeks (induction phase), then once weekly for 4 weeks if you're responding well, transitioning to once weekly or every other week for maintenance. Some patients respond well to a reduced schedule. Your Lumin Health clinical team will work with you to find the right cadence.
Safe and Comfortable Esketamine Treatment Environment at Lumin Health
Spravato (esketamine) therapy is proven to be safe when administered under medical supervision by our team of psychiatrists and psychiatric nurse practitioners. Each client is treated in a private room in a calm, comfortable environment. Throughout the treatment, our caring staff will ensure you feel relaxed and secure. After at least 4 years of clinical data, esketamine (Spravato) continues to show a robust safety profile.
Positive Effects of Spravato at Follow-Up
After the initial sessions, you may experience improved mood and enhanced overall well-being. We will closely monitor your progress and adjust the treatment plan as needed to ensure you achieve long-lasting relief.
How is Spravato different from traditional antidepressants like SSRIs?
Spravato differs from SSRIs and SNRIs in three fundamental ways: mechanism, onset, and effectiveness in treatment-resistant cases. Where SSRIs target serotonin reuptake, Spravato modulates glutamate through NMDA receptor antagonism—the first new mechanism for depression treatment FDA-approved in over 30 years. This translates to a dramatically faster onset: many patients report meaningful improvement within days, compared to the 4–6 weeks SSRIs typically need to take effect. Most importantly, Spravato is specifically approved and clinically validated for patients who have not responded adequately to two or more conventional antidepressants. In the pivotal Phase 3 trial, esketamine combined with a newly initiated oral antidepressant produced significantly greater symptom reduction than placebo plus antidepressant. It also works more reliably than augmenting agents (such as adding an antipsychotic) in treatment-refractory cases. For patients who have cycled through multiple SSRIs without relief, Spravato represents a fundamentally different therapeutic approach.
Is Spravato (esketamine) effective for all types of depression?
Spravato is FDA-approved for two specific conditions in adults: treatment-resistant depression (TRD), and depressive symptoms in adults with Major Depressive Disorder (MDD) experiencing acute suicidal ideation or behavior. It is not approved for general use across all depression types. The TRD designation specifically applies to patients who have not responded adequately to at least two different oral antidepressants tried at adequate dose and duration during the current depressive episode. For other forms of depression – including mild-to-moderate MDD where SSRIs or SNRIs have not yet been tried – conventional first-line treatments are typically recommended first. Spravato should always be considered under the guidance of a psychiatrist or psychiatric nurse practitioner who can assess your full treatment history, current symptoms, and response to prior interventions before determining whether you're a candidate. If you've tried two or more antidepressants without adequate relief, Spravato may be an appropriate next step in your treatment plan.
What clinical trials support Spravato's effectiveness?
Spravato's FDA approval rests on a rigorous Phase 3 clinical trial program. The pivotal Phase 3 trial tested esketamine plus a newly initiated oral antidepressant against placebo plus oral antidepressant in adults with treatment-resistant depression. The esketamine arm produced significantly greater reduction in depression symptoms at four weeks. Subsequent maintenance studies demonstrated that continued esketamine treatment substantially delayed depression relapse compared to placebo. The 2020 FDA approval expansion to include adults with Major Depressive Disorder experiencing acute suicidal ideation rested on additional trials specific to that population. Across these studies, esketamine has shown both rapid onset – often within 24 hours—and sustained effect when treatment is maintained. The body of evidence now spans more than four years of post-approval clinical data reinforcing its safety and efficacy profile, making esketamine one of the most thoroughly studied recent additions to the depression treatment landscape.
How is Spravato (esketamine) administered?
Spravato is administered as a nasal spray that you self-spray under the direct observation of a healthcare professional in a clinical setting. Each session takes approximately 2 hours total: a few minutes for the actual spray administration, followed by a 2-hour monitoring period as required by the FDA's REMS (Risk Evaluation and Mitigation Strategy) protocol. During monitoring, your blood pressure and overall response are checked at regular intervals while you rest in a private room. The standard induction protocol is twice-weekly sessions for the first four weeks, followed by once-weekly for the next four weeks if you're responding well, then transitioning to once-weekly or once-every-other-week for maintenance. Dosage typically starts at 56 mg and may increase to 84 mg based on response and tolerability. Your Lumin Health clinician determines the exact cadence and dose based on your individual response.
Is Spravato (esketamine) covered by insurance?
Yes – Spravato is covered by most major insurance plans for treatment-resistant depression in adults, including Blue Cross Blue Shield, Anthem, Aetna, UnitedHealthcare, Cigna, Harvard Pilgrim, and Medicare. Because Spravato is FDA-approved and delivered in a clinical setting, it qualifies for medical-benefit coverage rather than pharmacy-benefit—which often means lower out-of-pocket costs for patients. Most plans require prior authorization documenting that you've tried at least two oral antidepressants without adequate response. Lumin Health handles prior authorizations directly with your insurer as part of intake, so you don't have to navigate the paperwork alone. For most insured patients, out-of-pocket costs are minimal—often $10 to $25 per session. We verify coverage and estimated costs upfront during your consultation, so there are no surprise bills. If your plan doesn't cover Spravato, we can discuss self-pay options and alternative paths.
Lumin Health Locations
Newton Center
10 Langley Road, Suite 200
Newton, MA 02459Cambridge (Harvard Square)
50 Church Street, 3rd Floor
Cambridge, MA 02138Woburn
300 Tradecenter Drive, Suite 3400
Woburn, MA 01801Brookline
1101 Beacon Street, Suite 4E
Brookline, MA 02446Bethesda
4825 Bethesda Avenue
Suite 200
Bethesda, MD 20814
10 Langley Road, Suite 200
Newton, MA 02459Cambridge (Harvard Square)
50 Church Street, 3rd Floor
Cambridge, MA 02138Woburn
300 Tradecenter Drive, Suite 3400
Woburn, MA 01801Brookline
1101 Beacon Street, Suite 4E
Brookline, MA 02446Bethesda
4825 Bethesda Avenue
Suite 200
Bethesda, MD 20814
Monday - Friday, 8am - 6pm
Contact
